Among responding patients in the T-VEC arm, median time to response was 4.1 months, and more than half experienced ≥ 25% increase in the size of lesions or appearance of new lesions before achieving a response. This pattern of pseudoprogression is consistent with that seen with other immunotherapies19–23The full quote is above.
It reads as half the responders are having psuedoprogression is how I see that.
And then haven’t looked at your other article of 15%, but sounds like much higher than other immunotherapies.
And this is what CF33 is meant to outperform, and they’ve compared to preclinically, so don’t think it would be a stretch for CF33 rates to be higher still.
- Forums
- ASX - By Stock
- IMU
- Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
IMU
imugene limited
Add to My Watchlist
1.35%
!
37.5¢

Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-247
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $82.39M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 36.0¢ | $342.2K | 938.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 488 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 12566 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64143 | 0.365 |
8 | 258148 | 0.360 |
7 | 134035 | 0.355 |
16 | 165231 | 0.350 |
6 | 198970 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 12566 | 2 |
0.380 | 21000 | 2 |
0.385 | 17121 | 3 |
0.390 | 17530 | 3 |
0.395 | 222522 | 6 |
Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |